Poseida Therapeutics Inc (PSTX)
3.345
-0.12
(-3.32%)
USD |
NASDAQ |
May 16, 16:00
3.24
-0.10
(-3.14%)
Pre-Market: 08:08
Poseida Therapeutics Net Income (Quarterly): -24.27M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -24.27M |
| December 31, 2023 | -25.35M |
| September 30, 2023 | -31.78M |
| June 30, 2023 | -27.46M |
| March 31, 2023 | -38.85M |
| December 31, 2022 | -33.32M |
| September 30, 2022 | 70.41M |
| June 30, 2022 | -43.04M |
| March 31, 2022 | -58.06M |
| December 31, 2021 | 1.469M |
| September 30, 2021 | -42.42M |
| Date | Value |
|---|---|
| June 30, 2021 | -45.70M |
| March 31, 2021 | -38.31M |
| December 31, 2020 | -36.15M |
| September 30, 2020 | -34.41M |
| June 30, 2020 | -30.43M |
| March 31, 2020 | -28.78M |
| December 31, 2019 | -23.61M |
| September 30, 2019 | -20.95M |
| June 30, 2019 | -28.63M |
| March 31, 2019 | -13.33M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-58.06M
Minimum
Mar 2022
70.41M
Maximum
Sep 2022
-26.98M
Average
-31.10M
Median
Net Income (Quarterly) Benchmarks
| Biomea Fusion Inc | -39.06M |
| Cartesian Therapeutics Inc | -56.82M |
| Lantern Pharma Inc | -5.441M |
| NovaBay Pharmaceuticals Inc | -3.214M |
| Palatin Technologies Inc | -7.844M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 28.14M |
| Total Expenses (Quarterly) | 52.72M |
| EPS Diluted (Quarterly) | -0.25 |
| Enterprise Value | 184.27M |
| Profit Margin (Quarterly) | -86.26% |
| Earnings Yield | -35.28% |
| Normalized Earnings Yield | -35.28 |